Alto Neuroscience (Alto Neuroscience) Insider Ownership : 4.98 % (As of May. 26, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alto Neuroscience's insider ownership is 4.98%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alto Neuroscience's Institutional Ownership is 17.71%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alto Neuroscience's Float Percentage Of Total Shares Outstanding is 78.71%.

Alto Neuroscience Insider Ownership Historical Data

The historical data trend for Alto Neuroscience's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Insider Ownership Chart

Alto Neuroscience Historical Data

The historical data trend for Alto Neuroscience can be seen below:

	2024-02-29	2024-03-31	2024-04-30
Insider Ownership	5.28	4.98	4.98

Alto Neuroscience Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024